Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced that it has treated the first cohort of patients in its Phase I/IIa clinical study of its oncolytic virus, SEPREHVIR(R) (HSV1716) for the treatment of malignant pleural…
Virttu Biologics treats first cohort of patients in SEPREHVIR Phase I/IIa study
No comments:
Post a Comment